Target Name: CDH8
NCBI ID: G1006
Other Name(s): Nbla04261 | cadherin 8 | CADH8_HUMAN | Cadherin-8 | Putative protein product of Nbla04261 | cadherin 8, type 2 | Cadherin 8

Introduction to CDH8, A Potential Drug Target

CDH8, also known as cadherin 8, is a protein that belongs to the cadherin family of cell adhesion molecules. It plays a crucial role in cell-to-cell adhesion, cell migration, and tissue development. In recent years, CDH8 has emerged as an important drug target and biomarker in various diseases. This article will explore the significance of CDH8 as a potential therapeutic target and biomarker in different pathological conditions.

CDH8 as a Potential Drug Target

CDH8 has gained significant interest as a potential drug target due to its involvement in several disease processes. This protein is primarily expressed in the central nervous system, where it plays a crucial role in neuronal development and synaptic plasticity. Dysregulation of CDH8 has been implicated in various neurological disorders, including autism spectrum disorders (ASD) and schizophrenia.

Researchers have focused on developing therapeutic strategies that modulate CDH8 function to alleviate the symptoms associated with ASD and schizophrenia. By targeting CDH8, it may be possible to restore proper neuronal circuitry and improve cognitive functioning in affected individuals. Various drug discovery approaches, such as small molecules and biologics, are being explored to selectively modulate CDH8 activity.

One potential therapeutic strategy involves using small molecules that can specifically bind to CDH8 and either enhance or inhibit its activity. These molecules can potentially restore the disrupted cell adhesion and signaling pathways, thereby alleviating neurodevelopmental abnormalities. Another approach being investigated is the use of monoclonal antibodies that target CDH8, with the aim of modulating its function and restoring normal synaptic connectivity.

The development of CDH8-based therapies is still in its early stages, and extensive preclinical and clinical research is required to evaluate their safety and efficacy. However, the identification of CDH8 as a potential drug target already holds promising implications for the future treatment of neurological disorders.

CDH8 as a Biomarker

Apart from its role as a drug target, CDH8 also shows potential as a biomarker for certain diseases. Biomarkers are measurable indicators that provide significant information about the presence, progression, or prognosis of a disease. CDH8 expression levels have been found to be altered in several types of cancer, including colorectal, gastric, and bladder cancer.

In colorectal cancer, for example, studies have shown that CDH8 expression is significantly upregulated. This upregulation is associated with tumor progression, invasion, and metastasis. CDH8 levels have been correlated with poor prognosis, indicating that it could serve as a useful biomarker for predicting the aggressiveness of colorectal cancer. Additionally, measuring CDH8 expression levels in tumor tissues could help in stratifying patients for targeted therapies with CDH8 inhibitors.

Similarly, in gastric and bladder cancer, CDH8 has also been found to have clinical relevance as a biomarker. High CDH8 expression is associated with advanced tumor stage, lymph node metastasis, and unfavorable overall survival rates. This suggests that CDH8 could be a potential biomarker for predicting disease progression and prognosis in these cancers.

Conclusion

In conclusion, CDH8 has emerged as an important drug target and biomarker in various pathological conditions. Its involvement in neuronal development and synaptic plasticity makes it an attractive target for therapeutic interventions in neurological disorders such as ASD and schizophrenia. Additionally, the altered expression of CDH8 in several types of cancer has highlighted its potential as a biomarker for predicting disease progression and prognosis.

Further research is necessary to elucidate the underlying mechanisms of CDH8 in disease pathogenesis and to explore therapeutic strategies that specifically target this protein. With continued advancements in drug discovery and molecular diagnostic techniques, CDH8 holds great promise in the development of novel therapies and personalized medicine approaches for a range of diseases.

Protein Name: Cadherin 8

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types

More Common Targets

CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN | CDT1 | CDV3 | CDX1 | CDX2 | CDX4 | CDY1 | CDY1B | CDY2A | CDYL | CDYL2 | CEACAM1 | CEACAM16 | CEACAM16-AS1 | CEACAM18 | CEACAM19 | CEACAM20 | CEACAM21 | CEACAM22P | CEACAM3 | CEACAM4 | CEACAM5 | CEACAM6 | CEACAM7 | CEACAM8 | CEACAMP1